Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Li Wang | Executive Chairman of the Board, CEO & GM | 832.97k | -- | 1968 |
| Mr. Yunqing Wang | CFO, Joint Company Secretary & Executive Director | 1.3M | -- | 1985 |
| Ms. Peili Wang | Financial Manager & Executive Director | 878.64k | -- | 1984 |
| Dr. Bradley Stewart Hubbard D.V.M., DVM | Chief Medical Officer | -- | -- | 1959 |
| Ms. Siu Ying Kwok | Joint Company Secretary | -- | -- | 1985 |
| Mr. Tao Cai | Chairperson of the Board of Supervisors & Head of Technology of BRS | 176.16k | -- | 1987 |
Shanghai Bio-heart Biological Technology Co., Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 63
Description
Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People's Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available